Fosun's tourism culture premium is about 95%. Privatization resumed on December 11, and Fosun's tourism culture (01992) was announced. The company's shares resumed trading at 9: 00 am on December 11, 2024. Fosun's tourism culture plan was privatized by agreement and its listing status was revoked. The board of directors proposed to buy back shares at a price of HK$ 7.80 per share, which was 95% higher than the closing price before suspension.How to "bargain" the price difference of Chinese patent medicines? According to CCTV news, the National Medical Insurance Bureau responded that the price of proprietary Chinese medicines is affected by many factors, including the price of medicinal materials, production technology and brand value, in view of the large price difference of proprietary Chinese medicines and the problem of "bargaining". Centralized purchasing effectively squeezes the inflated price of drugs and improves the efficiency of capital use through market-oriented bidding and price-volume linkage. At the same time, the medical insurance bureau will strengthen monitoring and supervision to ensure the quality and supply of drugs and protect the rights and interests of patients.Facewall Intelligence has received a new round of financing of several hundred million yuan. Recently, Facewall Intelligence has completed a new round of financing of several hundred million yuan. This round of financing was jointly led by Loongson Venture Capital, Dinghui Baifu, Zhongguancun Science City Fund and Safran Investment Fund, and Beijing Artificial Intelligence Industry Investment Fund and Zero2IPO followed suit.
China's one-year interest rate swap hit a four-year low, and China's one-year interest rate swap (IRS) fell sharply this week, falling below the 1.50% mark for the first time since 2020. The data shows that the one-year interest rate swap was still around 1.50% at the beginning of Wednesday, and once fell to 1.4825% in the previous session, setting a new low since May 2020.The central parity of RMB against the US dollar was reported at 7.1843 yuan.Guojin Securities: In 25 years or the first year of commercial mass production of humanoid robots, Guojin Securities said that Huawei's overweight body intelligence has become a new direction, which is expected to bring deterministic AI technology to domestic robot manufacturers and help domestic OEMs accelerate their rise. In 25 years or the first year of commercial mass production of humanoid robots, the domestic and international industries have resonated, and the humanoid robot industry has ushered in a period of rapid development and has plate investment opportunities. It is suggested to focus on the screw, reducer, torque sensor and domestic robot.
Vietnam said that private equity giant KKR sought to expand its investment in the country. On the evening of December 10, the Vietnamese government website issued a statement saying that private equity investment company KKR was seeking to expand its investment opportunities in Vietnam. Su Lin, general secretary of the Central Committee of the Communist Party of Vietnam, expressed the hope that foreign investors, including American investors, will continue to increase their investment in Vietnam, especially in the fields of digital transformation, green transformation, renewable energy, clean energy and climate change. It is suggested that American enterprises, including KKR, continue to actively contribute to promoting bilateral cooperation, especially bilateral economic and scientific cooperation. David Petraeus, a partner of KKR, said that KKR is very optimistic about the investment prospects in Vietnam, and KKR Fund is looking for opportunities to expand cooperation and investment in Vietnam. He also promised to continue to support the development of Vietnam-US relations.The central parity of RMB against the US dollar was reported at 7.1843 yuan.Six countries' chemical companies set up resource recycling companies, including new material technology research and development business. According to the enterprise survey APP, Hubei Xingyang Resource Recycling Co., Ltd. was recently established, with the legal representative of Xu Jinchong and the registered capital of about 145 million yuan. Its business scope includes: new material technology research and development; Manufacturing of eco-environmental materials; Sales of eco-environmental materials; Lime and gypsum manufacturing; Manufacturing of light building materials; Environmental consulting services; Processing of renewable resources, etc. Enterprise equity penetration shows that the company is jointly owned by Hubei Huiyang New Materials Co., Ltd. and dangyang city Jiantou Asset Management Co., Ltd., a subsidiary of Liuguo Chemical.
Strategy guide
12-13
Strategy guide
Strategy guide
12-13
Strategy guide 12-13